Goldman Sachs Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
H.C. Wainwright Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
June 3, 2025 7:05 AM EDTH.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $20.00 price target on Iovanace Biotherapeutics (NASDAQ: IOVA).
The analyst commented: "In addition to disclosing updated data from C-144-01 and hosting a KOL discussion, Iovance presented poster a detailing its ongoing clinical trial assessing TIL therapy in solid tumors, including NSCLC. Recall, IOV-COM-202 is an open-label Phase 2 study evaluating lifileucel in solid tumors; cohort 3A is... More
Citizens JMP Reiterates Market Perform Rating on Iovanace Biotherapeutics (IOVA)
June 3, 2025 4:23 AM EDTCitizens JMP analyst Reni J. Benjamin reiterated a Market Perform rating on Iovanace Biotherapeutics (NASDAQ: IOVA).
The analyst commented, We reiterate our Market Perform rating on Iovance Biotherapeutics based on a discounted revenue multiple analysis. During ASCO, Iovance presented five-year outcomes from the C-144-01... More
Iovance Biotherapeutics (IOVA) Announces Publication on Amtagvi
June 2, 2025 9:30 AM EDTIovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Journal of Clinical Oncology has published the final analysis from the Phase 2 C-144-01 clinical trial evaluating the individualized T cell therapy Amtagvi® (lifileucel) in patients with advanced melanoma. These five-year follow-up results are being simultaneously presented during an oral session today at the 2025 American Society of... More
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
May 30, 2025 5:01 AM EDTCitizens JMP released an industry report discussing the abstract titles from companies in the firms coverage, and outside, to be presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting.
The analyst commented, Abstract titles for presenting companies were released on April 23. Companies in the Citizens' coverage... More
